Evolution Biotechnologies announces sponsorship of EMBO Viruses of Microbes meeting, Liverpool, UK, 18-22 July 2016

Bedford, UK, and Austin, Texas; July 8th 2016

Evolution Biotechnologies (www.evolutionbiotech.com), the company working to expand the use of biological control into medically important areas, today announced its sponsorship of the forthcoming EMBO Vpromoiruses of Microbes (#EMBOVoM2016) meeting in Liverpool (http://events.embo.org/16-virus-microbe/ ).

The company will attend the meeting both to promote its new activities in the area and to recruit staff for its expanded operations.

Dr. David Harper, Chief Officer of Evolution, said “I am delighted that the company is supporting this important meeting, and look forward to attending along with other company staff.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 / US company 6050853) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work is based on developing biological controls for of the house dust mite, with the company now expanding into phage therapy, a highly promising approach to controlling antimicrobial resistance. The development of additional technologies is planned for the future.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts;

Email:      enquiries@evolutionbiotech.com

Website:   www.evolutionbiotech.com